Arbeitsgemeinschaft medikamentoese Tumortherapie
45
6
9
26
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
15.6%
7 terminated/withdrawn out of 45 trials
78.8%
-7.7% vs industry average
11%
5 trials in Phase 3/4
8%
2 of 26 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (45)
Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP
Role: collaborator
Metastatic Breast Cancer in Austria
Role: lead
Genomic Testing and Resulting Medical Decisions
Role: lead
Lung Cancer Registry
Role: lead
AGMT Metastatic Colorectal Cancer Registry (mCRC) Third Line and Beyond
Role: lead
AGMT Austrian CLL (Chronic Lymphocytic Leukemia) Registry
Role: lead
Austrian Myeloid Registry
Role: lead
Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer
Role: lead
AGMT Austrian Lymphoma Registry
Role: lead
Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM
Role: lead
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
Role: lead
Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy
Role: lead
Registry on Hypomethylating Agents in Myeloid Neoplasms
Role: lead
Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM
Role: collaborator
Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN
Role: lead
Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)
Role: lead
Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL
Role: lead
Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL
Role: lead
Biomarker Directed Treatment in Metastatic Colorectal Cancer
Role: lead
Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients
Role: lead